Market Landscape: Sequencing

Sequencing has moved from a specialized research technique to foundational infrastructure across life science research, clinical testing, pharma/bio R&D, and many other fields. The ability to read nucleic acid sequences at scale underpins basic discovery, drug development, diagnostics, and population health programs worldwide. The tools and applications for sequencing have advanced rapidly, shaped by technologies that have evolved over decades, which continue to expand the capabilities and possibilities of genomic analysis.

The Market Landscape: Sequencing Report provides an in-depth resource for those navigating the highly competitive market for research-use sequencing. Sequencing represents one of the highest revenue techniques of the analytical laboratory instrumentation space. Its history is filled not only with innovation and triumphs in scientific advancements, but also with legal battles and geopolitics. To understand the state and direction of the market, it is important to understand the regulations and litigation that shape the market and its participants.

This report is valuable for strategic planners, product and marketing managers, business development teams, and investors with an interest in the sequencing market.

Key features of this report include:

• Detailed lists of recent & ongoing litigation, regulations, and market developments
• Analysis of the overall sequencing market, including segmented market sizing and 5-year forecasts by product type, region, end market, and function
• Analysis of vendor market shares
• Analysis of key vendors, including technology overviews, key business developments, and analyses of revenues segmented by product types, regions, and end markets
  • Illumina
  • MGI Tech
  • Oxford Nanopore
  • Pacific Biosciences
  • Thermo Fisher Scientific
• Profiles of recent market entrants:
  • Element Biosciences
  • Roche
  • Ultima Genomics